Memory Loss: A Practical Guide for Clinicians

Memory Loss: A Practical Guide for Clinicians

Volumn , Issue , 2011, Pages 1-303

  Budson, Andrew E ^a,b,c,d,e   Solomon, Paul R ^e,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Memory Clinic   (United States)

^f WILLIAMS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85162635055     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (284)

1. Alzheimer's Association (2010) 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6 158-194.
2. J.L. Cummings (2004) Alzheimer's disease. N. Engl. J Med. 351 56-67.
3. D.S. Geldmacher, G. Provenzano, T. McRae, et al. (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 51 937-944.
4. D. Getsios, J.J. Caro, G. Caro and K. Ishak (2001) Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 57 972-978.
5. G.T. Grossberg (2008) Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings. Drugs Aging 25 573-584.
6. K.A. Lyseng-Williamson and G.L. Plosker (2002) Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 20 919-942.
7. M.J. Moore, C.W. Zhu and E.C. Clipp (2001) Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. J. Gerontol. B Psychol. Sci. Soc. Sci. 56 S219-S228.
8. M. Sano, G.K. Wilcock, B. van Baelen, et al. (2003) The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int. J. Geriatr. Psychiatry 18 942-950.
9. A. Wimo, B. Winblad, K. Engedal, et al. (2003) An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord. 15 44-54.
10. A. Wimo, B. Winblad, A. Stoffler, et al. (2003) Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21 327-340.
11. D.A. Balota, M.J. Cortese, J.M. Duchek, et al. (1999) Veridical and false memories in healthy older adults and in dementia of the Alzheimer's type. Cogn. Neuropsychol. 16 361-384.
12. M.L. Bleecker, K. Bolla-Wilson, C. Kawas, et al. (1988) Age-specific norms for the Mini-Mental State Exam. Neurology 38 1565-1568.
13. G. Blessed, B.E. Tomlinson and M. Roth (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114 797-811.
14. S. Borson, J.M. Scanlan, J. Watanabe, et al. (2005) Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample. J. Am. Geriatr. Soc. 53 871-874.
15. H. Brunnstrom, L. Gustafson, U. Passant, et al. (2009) Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch. Gerontol. Geriatr. 49 146-149.
16. H. Damasio, T.J. Grabowski, D. Tranel, et al. (1996) A neural basis for lexical retrieval. Nature 380 499-505.
17. M.R. Eastwood, E. Lautenschlaeger and S. Corbin (1983) A comparison of clinical methods for assessing dementia. J. Am. Geriatr. Soc. 31 342-347.
18. M.F. Folstein, S.E. Folstein and P.R. McHugh (1975) A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 189-198.
19. J.E. Galvin, C.M. Roe, K.K. Powlishta, et al. (2005) The AD8: a brief informant interview to detect dementia. Neurology 65 559-564.
20. J.E. Galvin, C.M. Roe, M.A. Coats, et al. (2007) Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch. Neurol. 64 725-730.
21. T. Grimmer, G. Henriksen, H.J. Wester, et al. (2009) Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol. Aging 30 1902-1909.
22. M. Grut, A.F. Jorm, L. Fratiglioni, et al. (1993) Memory complaints of elderly people in a population survey: variation according to dementia stage and depression. J. Am. Geriatr. Soc. 41 1295-1300.
23. S. Jayadev, E.J. Steinbart, Y.Y. Chi, et al. (2008) Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease. Arch. Neurol. 65 373-378.
24. A.F. Jorm (1994) A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol. Med. 24 145-153.
25. A.F. Jorm (2004) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): a review. Int. Psychogeriatr. 16 275-293.
26. A.F. Jorm and P.A. Jacomb (1989) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol. Med. 19 1015-1022.
27. U. Khan, C. Crossley, L. Kalra, et al. (2008) Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 39 2943-2949.
28. D.S. Knopman and S. Ryberg (1989) A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch. Neurol. 46 141-145.
29. B.D. Lebowitz, J.L. Pearson, L.S. Schneider, et al. (1997) Diagnosis and treatment of depression in late life. Consensus statement update. JAMA 278 1186-1190.
30. Y. Li, J.S. Meyer and J. Thornby (2001) Depressive symptoms among cognitive normal versus cognitive impaired elderly subjects. Int. J. Geriatr. Psychiatry 16 455-461.
31. J.J. Locascio, J.H. Growdon and S. Corkin (1995) Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch. Neurol. 52 1087-1099.
32. B.A. Maron and J. Loscalzo (2009) The treatment of hyperhomocysteinemia. Annu. Rev. Med. 60 39-54.
33. E.F. Meulen, B. Schmand, J.P. van Campen, et al. (2004) The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J. Neurol. Neurosurg. Psychiatry 75 700-705.
34. J.W. Miller, R. Green, D.M. Mungas, et al. (2002) Homocysteine, vitamin B6, and vascular disease in Alzheimer's disease patients. Neurology 58 1471-1475.
35. Z.S. Nasreddine, N.A. Phillips, V. Bedirian, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53 695-699.
36. D. Nitz (2009) Parietal cortex, navigation, and the construction of arbitrary reference frames for spatial information. Neurobiol. Learn. Mem. 91 179-185.
37. D. Perani, S.F. Cappa, T. Schnur, et al. (1999) The neural correlates of verb and noun processing. A PET study. Brain 122(Pt 12), 2337-2344.
38. R.I. Pfeffer, T.T. Kurosaki, C.H. Harrah Jr, et al. (1982) Measurement of functional activities in older adults in the community. J Gerontol. 37(3), 323-329.
39. J.L. Price and J.C. Morris (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45 358-368.
40. T. Ribot (1881) Les Maladies de la Mémoire Paris: Félix Alcan
41. P. Rinaldi, P. Mecocci, C. Benedetti, et al. (2003) Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J. Am. Geriatr. Soc. 51 694-698.
42. J.O. Rinne, H. Ruottinen, J. Bergman, et al. (1999) Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67 737-741.
43. S. Seshadri, A. Beiser, J. Selhub, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 476-483.
44. D.A. Snowdon, L.H. Greiner, J.A. Mortimer, et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277 813-817.
45. P.R. Solomon and C.A. Murphy (2005) Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. Geriatrics 60 26-31.
46. P.R. Solomon and C.A. Murphy (2008) Early diagnosis and treatment of Alzheimer's disease. Expert Rev. Neurother. 8 769-780.
47. P.R. Solomon, A. Hirschoff, B. Kelly, et al. (1998) A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Arch. Neurol. 55 349-355.
48. P.R. Solomon, M. Brush, V. Calvo, et al. (2000) Identifying dementia in the primary care practice. Int. Psychogeriatr. 12 483-493.
49. P.R. Solomon, M.A. Ruiz and C.A. Murphy (2003) The Alzheimer's Disease Caregiver Questionnaire: initial validation of a screening instrument. Int. Psychogeriatr. 15(Suppl. 2), 87.
50. M. Tsolaki, V. Iakovidou, E. Papadopoulou, et al. (2002) Greek validation of the seven-minute screening battery for Alzheimer's disease in the elderly. Am. J. Alzheimers Dis. Other Demen. 17 139-148.
51. S. Zankd and B. Leipold (2001) The relationship between severity of dementia and subjective well-being. Aging Ment. Health 5 191-196.
52. Alzheimer's Association (2010) 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6 158-194.
53. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, fourth Ed Arlington, VA: American Psychiatric Publishing, Inc
54. M.L. Balthazar, F. Cendes and B.P. Damasceno (2008) Semantic error patterns on the Boston Naming Test in normal aging, amnesic mild cognitive impairment, and mild Alzheimer's disease: is there semantic disruption? Neuropsychology 22 703-709.
55. A.E. Budson, J.S. Simons, J.D. Waring, et al. (2007) Memory for the September 11, 2001, terrorist attacks one year later in patients with Alzheimer's disease, patients with mild cognitive impairment, and healthy older adults. Cortex 43 875-888.
56. J.L. Cobb, P.A. Wolf, R. Au, et al. (1995) The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology 45 1707-1712.
57. S. Fleminger, D.L. Oliver, S. Lovestone, et al. (2003) Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J. Neurol. Neurosurg. Psychiatry 74 857-862.
58. H. Hampel, K. Burger, S.J. Teipel, et al. (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 4 38-48.
59. O. Hansson, H. Zetterberg, P. Buchhave, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 228-234.
60. C. Holmes, D. Boche, D. Wilkinson, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 216-223.
61. K.A. Josephs, J.L. Whitwell, Z. Ahmed, et al. (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 63 204-212.
62. N.T. Lautenschlager, L.A. Cupples, V.S. Rao, et al. (1996) Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 46 641-650.
63. J.A. Luchsinger, M.X. Tang, S. Shea, et al. (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62 1972-1976.
64. R. Mayeux, R. Ottman, G. Maestre, et al. (1995) Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45 555-557.
65. A.C. McKee, R.C. Cantu, C.J. Nowinski, et al. (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68 709-735.
66. G. McKhann, D. Drachman, M. Folstein, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 939-944.
67. M. Mesulam (2004) The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn. Mem. 11 43-49.
68. M. Mesulam, P. Shaw, D. Mash, et al. (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-Alzheimer's disease continuum. Ann. Neurol. 55 815-828.
69. J.W. Miller, R. Green, D.M. Mungas, et al. (2002) Homocysteine, vitamin B6, and vascular disease in Alzheimer's disease patients. Neurology 58 1471-1475.
70. S. Seshadri, A. Beiser, J. Selhub, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 476-483.
71. D.A. Snowdon, S.J. Kemper, J.A. Mortimer, et al. (1996) Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275 528-532.
72. D.A. Snowdon, L.H. Greiner, J.A. Mortimer, et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277 813-817.
73. D.A. Snowdon, L.H. Greiner and W.R. Markesbery (2000) Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Ann. N. Y. Acad. Sci. 903 34-38.
74. K.A. Welsh, N. Butters, J.P. Hughes, et al. (1992) Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch. Neurol. 49 448-452.
75. G.K. Wilcock and M.M. Esiri (1982) Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci. 56 343-356.
76. G.A. Jicha and R.C. Petersen (2007) Mild cognitive impairment. J. Growdon, M. Rossor (Eds) The Dementias 2 Philadelphia, PA: Butterworth Heinemann
77. R.C. Petersen, R.G. Thomas, M. Grundman, et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 2379-2388.
78. G. McKhann, D. Drachman, M. Folstein, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 939-944.
79. M. Bhasin, E. Rowan, K. Edwards, et al. (2007) Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int. J. Geriatr. Psychiatry 22 890-895.
80. M. Emre, D. Aarsland, A. Albanese, et al. (2004) Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351 2509-2518.
81. T.J. Ferman, B.F. Boeve, G.E. Smith, et al. (2002) Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J. Int. Neuropsychol. Soc. 8 907-914.
82. A.J. Harding, G.A. Broe and G.M. Halliday (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125 391-403.
83. D.G. Harper, E.G. Stopa, A.C. McKee, et al. (2004) Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol. Aging 25 771-781.
84. I. McKeith, T. Del Ser, P. Spano, et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 2031-2036.
85. I.G. McKeith, D.W. Dickson, J. Lowe, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 1863-1872.
86. A.R. Merdes, L.A. Hansen, D.V. Jeste, et al. (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60 1586-1590.
87. R.H. Perry, D. Irving, G. Blessed, et al. (1989) Senile dementia of Lewy body type and spectrum of Lewy body disease. Lancet 1 1088.
88. T. Rahkonen, U. Eloniemi-Sulkava, S. Rissanen, et al. (2003) Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J. Neurol. Neurosurg. Psychiatry 74 720-724.
89. B. Ravina, M. Putt, A. Siderowf, et al. (2005) Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76 934-939.
90. R.S. Turner, C.J. D'Amato, R.D. Chervin, et al. (2000) The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology 55 1730-1732.
91. A.P. Auchus, H.R. Brashear, S. Salloway, et al. (2007) Galantamine treatment of vascular dementia: a randomized trial. Neurology 69 448-458.
92. C. Ballard, M. Sauter, P. Scheltens, et al. (2008) Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr. Med. Res. Opin. 24 2561-2574.
93. S. Black, G.C. Roman, D.S. Geldmacher, et al. (2003) Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34 2323-2330.
94. T. Erkinjuntti, A. Kurz, S. Gauthier, et al. (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359 1283-1290.
95. T. Erkinjuntti, S. Gauthier, R. Bullock, et al. (2008) Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J. Psychopharmacol. 22 761-768.
96. A. Federico, S. Bianchi and M.T. Dotti (2005) The spectrum of mutations for CADASIL diagnosis. Neurol. Sci. 26 117-124.
97. G. Gold, P. Giannakopoulos, J.C. Montes-Paixao, et al. (1997) Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 49 690-694.
98. G. Gold, C. Bouras, A. Canuto, et al. (2002) Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am. J. Psychiatry 159 82-87.
99. H. Kavirajan and L.S. Schneider (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 6 782-792.
100. R. Moretti, P. Torre, R.M. Antonello, et al. (2003) Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am. J. Alzheimers Dis. Other Demen. 18 265-272.
101. J.M. Orgogozo, A.S. Rigaud, A. Stoffler, et al. (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33 1834-1839.
102. L. Pantoni, F. Pescini, S. Nannucci, et al. (2010) Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology 74 57-63.
103. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 250-260.
104. G.C. Roman, D.G. Wilkinson, R.S. Doody, et al. (2005) Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord. 20 338-344.
105. G. Wilcock, H.J. Mobius and A. Stoffler (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 17 297-305.
106. D. Wilkinson, R. Doody, R. Helme, et al. (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61 479-486.
107. Anonymous (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Neurosurg. Psychiatry 57 416-418.
108. E.D. Huey, C. Garcia, E.M. Wassermann, et al. (2008) Stimulant treatment of frontotemporal dementia in 8 patients. J. Clin. Psychiatry 69 1981-1982.
109. C.M. Kipps and J.R. Hodges (2007) Frontotemporal dementia syndromes. J.H. Growdon, M. Rossor (Eds) The Dementias 2 Philadelphia PA: Butterworth-Heinemann 112-140.
110. E.R. Maher, E.M. Smith and A.J. Lees (1985) Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J. Neurol. Neurosurg. Psychiatry 48 1234-1239.
111. H. Oba, A. Yagishita, H. Terada, et al. (2005) New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 64 2050-2055.
112. A. Varrone, M. Pagani, E. Salvatore, et al. (2007) Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 34 1071-1081.
113. M. Warmuth-Metz, M. Naumann, I. Csoti, et al. (2001) Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch. Neurol. 58 1076-1079.
114. R. Murray, M. Neumann, M.S. Forman, et al. (2007) Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 68 1274-1283.
115. J.L. Whitwell, C.R. Jack Jr., J.E. Parisi, et al. (2007) Rates of cerebral atrophy differ in different degenerative pathologies. Brain 130 1148-1158.
116. P.M. Black (1980) Idiopathic normal-pressure hydrocephalus. Results of shunting in 62 patients. J. Neurosurg. 52 371-377.
117. P.K. Eide and W. Sorteberg (2010) Diagnostic intracranial pressure monitoring and surgical management in idiopathic normal pressure hydrocephalus: a 6-year review of 214 patients. Neurosurgery 66 80-91.
118. N. Relkin, A. Marmarou, P. Klinge, et al. (2005) Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 57 S4-S16.
119. N. Tanaka, S. Yamaguchi, H. Ishikawa, et al. (2009) Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan: the Osaki-Tajiri project. Neuroepidemiology 32 171-175.
120. R.J. Cordery, K. Alner, L. Cipolotti, et al. (2005) The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. J. Neurol. Neurosurg. Psychiatry 76 330-336.
121. M.D. Geschwind, H. Shu, A. Haman, et al. (2008) Rapidly progressive dementia. Ann. Neurol. 64 97-108.
122. A. Kong, T. Kleinig, A. Van der Vliet, et al. (2008) MRI of sporadic Creutzfeldt-Jakob disease. J. Med. Imaging Radiat. Oncol. 52 318-324.
123. S.H. Yi, K.C. Park, S.S. Yoon, et al. (2008) Relationship between clinical course and diffusion-weighted MRI findings in sporadic Creutzfeldt-Jakob disease. Neurol. Sci. 29 251-255.
124. J. Attems and K.A. Jellinger (2006) Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 66 775.
125. W.A. Brown (2005) Pseudodementia: Issues in diagnosis. Applied Neurology 40-43.
126. L.H. Coker, M.A. Espeland, S.R. Rapp, et al. (2010) Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J. Steroid Biochem. Mol. Biol. 118 304-310.
127. M.C. Craig, P.M. Maki and D.G. Murphy (2005) The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 4 190-194.
128. J.L. Cummings, W. Ross, J. Absher, et al. (1995) Depressive symptoms in Alzheimer disease: assessment and determinants. Alzheimer Dis. Assoc. Disord. 9 87-93.
129. C. Duyckaerts, B. Delatour and M.C. Potier (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118 5-36.
130. M.D. Geschwind, H. Shu, A. Haman, et al. (2008) Rapidly progressive dementia. Ann. Neurol. 64 97-108.
131. A.E. Gold, I.J. Deary, R.W. Jones, et al. (1994) Severe deterioration in cognitive function and personality in five patients with long-standing diabetes: a complication of diabetes or a consequence of treatment? Diabet. Med. 11 499-505.
132. A. Harding, G. Halliday, D. Caine, et al. (2000) Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. Brain 123 141-154.
133. V.W. Henderson (2009) Aging, estrogens, and episodic memory in women. Cogn. Behav. Neurol. 22 205-214.
134. J.H. Ma, Y.J. Kim, W.J. Yoo, et al. (2009) MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging. Neuroradiology 51 641-649.
135. R. Mayeux, R. Ottman, G. Maestre, et al. (1995) Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45 555-557.
136. A.C. McKee, R.C. Cantu, C.J. Nowinski, et al. (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68 709-735.
137. M. Oscar-Berman and K. Marinkovic (2007) Alcohol: effects on neurobehavioral functions and the brain. Neuropsychol. Rev. 17 239-257.
138. F. Panza, V. Frisardi, C. Capurso, et al. (2010) Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am. J. Geriatr. Psychiatry 18 98-116.
139. J.D. Schmahmann and J.C. Sherman (1998) The cerebellar cognitive affective syndrome. Brain 121(Pt 4), 561-579.
140. J.D. Schmahmann and D. Caplan (2006) Cognition, emotion and the cerebellum. Brain 129 290-292.
141. G. Stanek and F. Strle (2009) Lyme borreliosis: a European perspective on diagnosis and clinical management. Curr. Opin. Infect. Dis. 22 450-454.
142. R. Stickgold (2005) Sleep-dependent memory consolidation. Nature 437 1272-1278.
143. R. Stickgold (2006) Neuroscience: a memory boost while you sleep. Nature 444 559-560.
144. R.E. Tractenberg, M.F. Weiner, M.B. Patterson, et al. (2003) Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 16 94-99.
145. S.I. Finkel (2001) Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J. Clin. Psychiatry 62(Suppl. 21), 3-6.
146. S.I. Finkel (2002) Behavioral and psychological symptoms of dementia. Assisting the caregiver and managing the patient. Geriatrics 57 44-46.
147. J. Birks (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. CD005593
148. G. Blessed, B.E. Tomlinson and M. Roth (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114 797-811.
149. R. Bullock, J. Touchon, H. Bergman, et al. (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr. Med. Res. Opin. 21 1317-1327.
150. C. Christodoulou, P. Melville, W.F. Scherl, et al. (2006) Effects of donepezil on memory and cognition in multiple sclerosis. J. Neurol. Sci. 245 127-136.
151. J.L. Cummings (2004) Alzheimer's disease. N. Engl. J. Med. 351 56-67.
152. M.F. Folstein, S.E. Folstein and P.R. McHugh (1975) A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 189-198.
153. R.W. Jones, H. Soininen, K. Hager, et al. (2004) A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int. J. Geriatr. Psychiatry 19 58-67.
154. Y.W. Kim, D.Y. Kim, J.C. Shin, et al. (2009) The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury. Clin. Neuropharmacol. 32 63-68.
155. I. McKeith, T. Del Ser, P. Spano, et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 2031-2036.
156. R. Moretti, P. Torre, R.M. Antonello, et al. (2003) Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am. J. Alzheimers Dis. Other. Demen. 18 265-272.
157. R.C. Petersen, R.G. Thomas, M. Grundman, et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 2379-2388.
158. G. Wilcock, I. Howe, H. Coles, et al. (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20 777-789.
159. D.G. Wilkinson, A.P. Passmore, R. Bullock, et al. (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int. J. Clin. Pract. 56 441-446.
160. D. Aarsland, C. Ballard, Z. Walker, et al. (2009) Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8 613-618.
161. A. Atri, L.W. Shaughnessy, J.J. Locascio, et al. (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 22 209-221.
162. A.L. Boxer, A.M. Lipton, K. Womack, et al. (2009) An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 23 211-217.
163. J. Diehl-Schmid, H. Forstl, R. Perneczky, et al. (2008) A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J. Geriatr. Psychiatry 23 754-759.
164. O.L. Lopez, J.T. Becker, A.S. Wahed, et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80 600-607.
165. M. Merello, M.I. Nouzeilles, A. Cammarota, et al. (1999) Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin. Neuropharmacol. 22 273-276.
166. J.T. Olin, V. Bhatnagar, P. Reyes, et al. (2010) Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry 25 419-426.
167. J.M. Orgogozo, A.S. Rigaud, A. Stoffler, et al. (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33 1834-1839.
168. C.G. Parsons, W. Danysz and G. Quack (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 38 735-767.
169. C.G. Parsons, A. Stoffler and W. Danysz (2007) Memantine: an NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology 53 699-723.
170. M. Peeters, J.M. Maloteaux and E. Hermans (2003) Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci. Lett. 343 205-209.
171. A.P. Porsteinsson, G.T. Grossberg, J. Mintzer, et al. (2008) Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 5 83-89.
172. B. Reisberg, R. Doody, A. Stoffler, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 1333-1341.
173. R. Spanagel, B. Eilbacher and R. Wilke (1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat: a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 262 21-26.
174. M.M. Swanberg (2007) Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Disord. 21 164-166.
175. P.N. Tariot, M.R. Farlow, G.T. Grossberg, et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 317-324.
176. S.H. Wang and R.G. Morris (2010) Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu. Rev. Psychol. 61 49-79.
177. B. Winblad and N. Poritis (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14 135-146.
178. P.S. Aisen, S. Egelko, H. Andrews, et al. (2003) A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am. J. Geriatr. Psychiatry 11 246-249.
179. P.S. Aisen, K.A. Schafer, M. Grundman, et al. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 2819-2826.
180. P.S. Aisen, L.S. Schneider, M. Sano, et al. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300 1774-1783.
181. P.J. Connelly, N.P. Prentice, G. Cousland, et al. (2008) A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int. J. Geriatr. Psychiatry 23 155-160.
182. S.T. DeKosky, J.D. Williamson, A.L. Fitzpatrick, et al. (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300 2253-2262.
183. D.M. Kado, A.S. Karlamangla, M.H. Huang, et al. (2005) Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am. J. Med. 118 161-167.
184. P.L. LeBars, M.M. Katz, N. Berman, et al. (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278 1327-1332.
185. I.M. Lee, N.R. Cook, J.M. Gaziano, et al. (2005) Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study—a randomized controlled trial. JAMA 294 56-65.
186. E. Lonn, J. Bosch, S. Yusuf, et al. (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 1338-1347.
187. J.A. Luchsinger, M.X. Tang, S. Shea, et al. (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62 1972-1976.
188. J.A. Luchsinger, M.X. Tang, J. Miller, et al. (2008) Higher folate intake is related to lower risk of Alzheimer's disease in the elderly. J. Nutr. Health Aging 12 648-650.
189. T. Matsui, M. Nemoto, M. Maruyama, et al. (2005) Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease. Neurodegener. Dis. 2 299-304.
190. E.R. Miller III, R. Pastor-Barriuso, D. Dalal, et al. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142 37-46.
191. J.W. Miller, R. Green, D.M. Mungas, et al. (2002) Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 58 1471-1475.
192. R.C. Petersen, R.G. Thomas, M. Grundman, et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 2379-2388.
193. J.F. Quinn, R. Raman, R.G. Thomas, et al. (2009) A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease Alzheimer's Association International Conference on Alzheimer's Disease, Presentation O1-04-02, 7/12/2009
194. D. Religa, M. Styczynska, B. Peplonska, et al. (2003) Homocysteine, apolipoprotein E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 16 64-70.
195. J.B. Rich, D.X. Rasmusson, M.F. Folstein, et al. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45 51-55.
196. P. Sachdev, R. Parslow, C. Salonikas, et al. (2004) Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch. Neurol. 61 1369-1376.
197. M. Sano, C. Ernesto, R.G. Thomas, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 1216-1222.
198. E.J. Schaefer, V. Bongard, A.S. Beiser, et al. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 63 1545-1550.
199. T.M. Scott, K.L. Tucker, A. Bhadelia, et al. (2004) Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am. J. Geriatr. Psychiatry 12 631-638.
200. S. Seshadri, A. Beiser, J. Selhub, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 476-483.
201. P.R. Solomon, F. Adams, A. Silver, et al. (2002) Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288 835-840.
202. W.F. Stewart, C. Kawas, M. Corrada, et al. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 626-632.
203. Y. Sun, C.J. Lu, K.L. Chien, et al. (2007) Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin. Ther. 29 2204-2214.
204. C.A. Szekely, J.E. Thorne, P.P. Zandi, et al. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 159-169.
205. M.G. Traber (2008) Vitamin E and K interactions: a 50-year-old problem. Nutr. Rev. 66 624-629.
206. E.E. Tuppo and H.R. Arias (2005) The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell. Biol. 37 289-305.
207. S. Yusuf, G. Dagenais, J. Pogue, et al. (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 154-160.
208. P.S. Aisen, D. Saumier, R. Briand, et al. (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67 1757-1763.
209. S.T. DeKosky, M.D. Ikonomovic and S. Gandy (2010) Traumatic brain injury: football, warfare, and long-term effects. N. Engl. J. Med. 363 1293-1296.
210. S. Gilman, M. Koller, R.S. Black, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with Alzheimer's disease in an interrupted trial. Neurology 64 1553-1562.
211. C.A. Gold and A.E. Budson (2008) Memory loss in Alzheimer's disease: implications for development of therapeutics. Expert Rev. Neurother. 8 1879-1891.
212. C. Haass and D.J. Selkoe (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8 101-112.
213. J. Hardy and D.J. Selkoe (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 353-356.
214. C. Holmes, D. Boche, D. Wilkinson, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 216-223.
215. B.P. Imbimbo (2009) Why did tarenflurbil fail in Alzheimer's disease? J. Alzheimers Dis. 17 757-760.
216. H.W. Klafki, M. Staufenbiel, J. Kornhuber, et al. (2006) Therapeutic approaches to Alzheimer's disease. Brain 129 2840-2855.
217. E.M. Mandelkow and E. Mandelkow (1998) Tau in Alzheimer's disease. Trends Cell. Biol. 8 425-427.
218. A.C. McKee, R.C. Cantu, C.J. Nowinski, et al. (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68 709-735.
219. H. Moreno, E. Yu, G. Pigino, et al. (2009) Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc. Natl Acad. Sci. U.S.A. 106 5901-5906.
220. J.A. Nicoll, D. Wilkinson, C. Holmes, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 448-452.
221. S. Salloway, R. Sperling, S. Gilman, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 2061-2070.
222. P.R. Solomon and A.L. Budson (2003) Alzheimer's disease. Clinical Symposia: Dannemiller Memorial Educational Foundation (formerly Ciba Symposium) 54(1), 1-44.
223. P.R. Solomon and C.M. Murphy (2008) Early diagnosis and treatment of Alzheimer's disease. Expert Rev. Neurother. 8(5), 769-780.
224. L. Sparks (2009) Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry 80 1-2.
225. B. Vellas, R. Black, L.J. Thal, et al. (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6 144-151.
226. B. Wolozin, J. Brown III, C. Theisler, et al. (2004) The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug. Rev. 10 127-146.
227. T.N. Akbaraly, F. Portet, S. Fustinoni, et al. (2009) Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology 73 854-861.
228. D. Albani, L. Polito and G. Forloni (2010) Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J. Alzheimers Dis. 19 11-26.
229. B.A. Ally, C.A. Gold and A.E. Budson (2009) The picture superiority effect in patients with Alzheimer's disease and mild cognitive impairment. Neuropsychologia 47 595-598.
230. C. Berr, F. Portet, I. Carriere, et al. (2009) Olive oil and cognition: results from the Three-City Study. Dement. Geriatr. Cogn. Disord. 28 357-364.
231. J. Boyke, J. Driemeyer, C. Gaser, et al. (2008) Training-induced brain structure changes in the elderly. J. Neurosci. 28 7031-7035.
232. S.C. Burgener, L. Buettner, B.K. Coen, et al. (2008) Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease (AD). J. Nutr. Health Aging 12 18-21.
233. S.C. Burgener, L.L. Buettner, E. Beattie, et al. (2009) Effectiveness of community-based, nonpharmacological interventions for early-stage dementia: conclusions and recommendations. J. Gerontol. Nurs. 35 50-57.
234. S.J. Colcombe, K.I. Erickson, P.E. Scalf, et al. (2006) Aerobic exercise training increases brain volume in aging humans. J. Gerontol. A. Biol. Sci. Med. Sci. 61 1166-1170.
235. V. Galvan and D.E. Bredesen (2007) Neurogenesis in the adult brain: implications for Alzheimer's disease. CNS Neurol. Disord. Drug Targets 6 303-310.
236. B.A. Gordon, E.I. Rykhlevskaia, C.R. Brumback, et al. (2008) Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. Psychophysiology 45 825-838.
237. Y. Gu, J.W. Nieves, Y. Stern, et al. (2010) Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol. 67 699-706..
238. G.T. Leung, A.W. Fung, C.W. Tam, et al. (2010) Examining the association between participation in late-life leisure activities and cognitive function in community-dwelling elderly Chinese in Hong Kong. Int. Psychogeriatr. 22 2-13.
239. J. Nithianantharajah and A.J. Hannan (2009) The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog. Neurobiol. 89 369-382.
240. N. Scarmeas, J.A. Luchsinger, N. Schupf, et al. (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302 627-637.
241. N. Scarmeas, Y. Stern, R. Mayeux, et al. (2009) Mediterranean diet and mild cognitive impairment. Arch. Neurol. 66 216-225.
242. J. Weuve, J.H. Kang, J.E. Manson, et al. (2004) Physical activity, including walking, and cognitive function in older women. JAMA 292 1454-1461.
243. G.S. Alexopoulos, R.C. Abrams, R.C. Young, et al. (1988) Cornell Scale for Depression in Dementia. Biol. Psychiatry 23 271-284.
244. J. Cohen-Mansfield (1986) Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J. Am. Geriatr. Soc. 34 722-727.
245. J.L. Cummings, M. Mega, K. Gray, et al. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 2308-2314.
246. S.I. Finkel, G. Costa e Silva, Cohen, et al. (1996) Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 8(Suppl. 3), 497-500.
247. M.S. Mega, J.L. Cummings, T. Fiorello, et al. (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 130-135.
248. B. Reisberg, J. Borenstein, S.P. Salob, et al. (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48(Suppl.), 9-15.
249. J.A. Yesavage, T.L. Brink, T.L. Rose, et al. (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 17 37-49.
250. Alzheimer's Association (2010) 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6 158-194.
251. M. Baumgarten, J.A. Hanley, C. Infante-Rivard, et al. (1994) Health of family members caring for elderly persons with dementia. A longitudinal study. Ann. Intern. Med. 120 126-132.
252. M. Baumgarten, R.N. Battista, C. Infante-Rivard, et al. (1997) Use of physician services among family caregivers of elderly persons with dementia. J. Clin. Epidemiol. 50 1265-1272.
253. B. Carpenter and J. Dave (2004) Disclosing a dementia diagnosis: a review of opinion and practice, and a proposed research agenda. Gerontologist 44 149-158.
254. J.K. Coste (2003) Learning to Speak Alzheimer's: a Groundbreaking Approach for Everyone Dealing with the Disease Boston: Houghton Mifflin
255. M. Crespo, J. Lopez and S.H. Zarit (2005) Depression and anxiety in primary caregivers: a comparative study of caregivers of demented and nondemented older persons. Int. J. Geriatr. Psychiatry 20 591-592.
256. M. Doraiswamy and L.P. Gwyther (2008) The Alzheimer's Action Plan New York: St Martin's Press
257. M. Ferrara, E. Langiano, T. Di Brango, et al. (2008) Prevalence of stress, anxiety and depression in with Alzheimer caregivers. Health Qual. Life Outcomes 6 93.
258. M.L. Laakkonen, M.M. Raivio, U. Eloniemi-Sulkava, et al. (2008) How do elderly spouse care givers of people with Alzheimer disease experience the disclosure of dementia diagnosis and subsequent care? J. Med. Ethics 34 427-430.
259. M.A. Lieberman and L. Fisher (2001) The effects of nursing home placement on family caregivers of patients with Alzheimer's disease. Gerontologist 41 819-826.
260. N.L. Mace and P.V. Rabins (2006) The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life Baltimore: Johns Hopkins University Press
261. R. Schulz, A.T. O'Brien, J. Bookwala, et al. (1995) Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 35 771-791.
262. P.D. Bruen, W.J. McGeown, M.F. Shanks, et al. (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain 131 2455-2463.
263. A.J. Lerner, M. Strauss and S.A. Sami (2007) Recognizing apathy in Alzheimer's disease. Geriatrics 62 14-17.
264. G.A. Marshall, L. Monserratt, D. Harwood, et al. (2007) Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch. Neurol. 64 1015-1020.
265. S. Nakaaki, Y. Murata, J. Sato, et al. (2008) Association between apathy/depression and executive function in patients with Alzheimer's disease. Int. Psychogeriatr. 20 964-975.
266. F. Panza, V. Frisardi, C. Capurso, et al. (2010) Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am. J. Geriatr. Psychiatry 18 98-116.
267. S.E. Starkstein, R. Mizrahi, A.A. Capizzano, et al. (2009) Neuroimaging correlates of apathy and depression in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 21 259-265.
268. P. Tagariello, P. Girardi and M. Amore (2009) Depression and apathy in dementia: same syndrome or different constructs? A critical review. Arch. Gerontol. Geriatr. 49 246-249.
269. J.L. Cummings, T. McRae and R. Zhang (2006) Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 14 605-612.
270. J.L. Cummings, J. Mackell and D. Kaufer (2008) Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement. 4 49-60.
271. F. Di Iulio, K. Palmer, C. Blundo, et al. (2010) Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes. Int. Psychogeriatr. 22 629-640.
272. A. Gabelle and Y. Dauvilliers (2010) Editorial: sleep and dementia. J. Nutr. Health Aging 14 201-202.
273. M.S. Mega, J.L. Cummings, T. Fiorello, et al. (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 130-135.
274. M.S. Mega, D.M. Masterman, S.M. O'Connor, et al. (1999) The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch. Neurol. 56 1388-1393.
275. A.B. Neikrug and S. Ancoli-Israel (2010) Sleep disturbances in nursing homes. J. Nutr. Health Aging 14 207-211.
276. S.K. Roepke and S. Ancoli-Israel (2010) Sleep disorders in the elderly. Indian J. Med. Res. 131 302-310.
277. R.M. Dubinsky, A.C. Stein and K. Lyons (2000) Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 54 2205-2211.
278. D.J. Iverson, G.S. Gronseth, M.A. Reger, et al. (2010) Practice parameter update: evaluation and management of driving risk in dementia. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74 1316-1324.
279. K.L. Triebel, R. Martin, H.R. Griffith, et al. (2009) Declining financial capacity in mild cognitive impairment: a 1-year longitudinal study. Neurology 73 928-934.
280. T.N. Akbaraly, F. Portet, S. Fustinoni, et al. (2009) Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology 73 854-861.
281. J. Boyke, J. Driemeyer, C. Gaser, et al. (2008) Training-induced brain structure changes in the elderly. J. Neurosci. 28 7031-7035.
282. N.T. Lautenschlager, L.A. Cupples, V.S. Rao, et al. (1996) Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 46 641-650.
283. G.T. Leung, A.W. Fung, C.W. Tam, et al. (2010) Examining the association between participation in late-life leisure activities and cognitive function in community-dwelling elderly Chinese in Hong Kong. Int. Psychogeriatr. 22 2-13.
284. N. Scarmeas, J.A. Luchsinger, N. Schupf, et al. (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302 627-637.